Quarterly ResultAug 11, 2026, 07:22 AM
Aura Biosciences Q2 Net Loss $(45.6)M; Raises $280.8M, Repurchases Shares
AI Summary
Aura Biosciences reported a net loss of $(79.3) million for the six months ended June 30, 2026, an increase from $(54.5) million in the prior year, driven by higher research and development and general and administrative expenses. The company significantly bolstered its financial position through a follow-on offering in May 2026, raising approximately $280.8 million in net proceeds. A portion of these funds, $39.0 million, was used to repurchase 6,922,870 shares of common stock. Aura Biosciences anticipates its current cash and equivalents will fund operations for at least 12 months, while topline data for its lead product candidate, bel-sar, is not expected until the second half of 2027.
Key Highlights
- Net loss for the six months ended June 30, 2026, increased to $(79.3) million from $(54.5) million YoY.
- Research and development expenses rose to $58.7 million for the six months, up from $46.2 million YoY.
- General and administrative expenses significantly increased to $24.2 million for the six months, from $11.4 million YoY.
- Completed a follow-on offering in May 2026, generating approximately $280.8 million in net proceeds.
- Repurchased 6,922,870 common shares for $39.0 million from Matrix Capital Management Master Fund, LP.
- Cash, cash equivalents, and marketable securities totaled $323.8 million as of June 30, 2026.
- Topline data for the pivotal Phase 3 clinical trial of belzupacap sarotalocan (bel-sar) is expected in H2 2027.
- Company expects current capital to fund operations for at least 12 months from the filing date.
Price Impact
More from AURA